Intellia Therape Rg
NTLA
USD
STOCK MARKET:
NMS
Closed
 
...
Large gap with delayed quotes
Last quote
04/25/2026 - 02:00:00
Bid
04/27/2026 - 14:58:17
Bid
Volume
Ask
04/27/2026 - 14:58:17
Ask
Volume
13.63
-2.24 ( -14.11% )
14.21
1,000
14.28
1,600
More information
Analysis by TheScreener
24.04.2026
Evaluation Slightly negative  
Interest Weak  
Sensibility High  
Analysis date: 24.04.2026
Global Evaluation
  Slightly negative
The stock is classified in the slightly negative zone since 07.04.2026.
Interest
  Weak
Two stars since 17.04.2026.
Earnings Rev Trend
  Positive
 
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 24.04.2026 at a price of 13.63.
Evaluation
  Strongly overvalued
 
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
  Neutral
 
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 07.04.2026.
4wk Rel Perf
  -2.88%
 
The four-week dividend-adjusted underperformance versus SP500 is 2.88%.
Sensibility
  High
High, no change over 1 year.
Bear Market Factor
  High
On average, the stock has a tendency to amplify the drops in the index by 1.33%.
Bad News Factor
  Low
When the stock's pressure is specific, the market sanction on average is 7.80%.
Mkt Cap in $bn
  1.61
With a market capitalization <$2bn, INTELLIA THERAPEUTICS is considered a small-cap stock.
G/PE Ratio
  1.14
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of .
LT P/E
  -6.54
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
  7.48%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
  17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
  0.00%
The company is not paying a dividend.
Beta
  167
For 1% of index variation, the stock varies on average by 1.67%.
Correlation
  0.21
Stock movements are strongly independent of index variations.
Value at Risk
  11.42
The value at risk is estimated at USD 11.42. The risk is therefore 83.79%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
  30.04.2021